CVM · Cel-Sci Corporation Common Stock
View on chartInsiders & Stakes
| KERSTEN GEERT R Chief Executive Officer | ▲ Buy | Grant | 318,763 Shares held | 9/30/2026 | View profile |
| ZIMMERMAN DANIEL H Senior Vice President | ▲ Buy | Grant | 120,226 Shares held | 9/30/2022 | View profile |
| PRICHEP PATRICIA B Chief Financial Officer | ▲ Buy | Grant | 19,571 Shares held | 9/30/2026 | View profile |
| TALOR EYAL Chief Scientific Officer | ▲ Buy | Grant | 10,483 Shares held | 9/30/2026 | View profile |
| Watson Robert Eugene Director | ▲ Buy | Open Market | 3,733 Shares held | 7/25/2025 | View profile |
Transaction History
| TALOR EYAL | ▲ Buy | Grant | 1,165 | $2K | 9/30/2026 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 2,082 | $4K | 9/30/2026 |
| KERSTEN GEERT R | ▲ Buy | Grant | 2,621 | $5K | 9/30/2026 |
| KERSTEN GEERT R | ▲ Buy | Open Market | 100,000 | $138K | 8/25/2026 |
| TALOR EYAL | ▲ Buy | Grant | 2,307 | $2K | 6/30/2026 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 4,125 | $4K | 6/30/2026 |
| KERSTEN GEERT R | ▲ Buy | Grant | 5,192 | $5K | 6/30/2026 |
| KERSTEN GEERT R | ▲ Buy | Open Market | 300,000 | $360K | 5/14/2026 |
| KERSTEN GEERT R | ▲ Buy | Open Market | 100,000 | $119K | 5/13/2026 |
| TALOR EYAL | ▲ Buy | Grant | 747 | $2K | 3/31/2026 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 1,336 | $4K | 3/31/2026 |
| KERSTEN GEERT R | ▲ Buy | Grant | 1,682 | $5K | 3/31/2026 |
| KERSTEN GEERT R | ▲ Buy | Open Market | 38,023 | $200K | 1/22/2026 |
| TALOR EYAL | ▲ Buy | Grant | 456 | $2K | 12/31/2025 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 815 | $4K | 12/31/2025 |
| KERSTEN GEERT R | ▲ Buy | Grant | 998 | $5K | 12/31/2025 |
| KERSTEN GEERT R | ▲ Buy | Open Market | 8,389 | $50K | 12/4/2025 |
| TALOR EYAL | ▲ Buy | Grant | 260 | $2K | 9/30/2025 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 466 | $4K | 9/30/2025 |
| KERSTEN GEERT R | ▲ Buy | Grant | 570 | $5K | 9/30/2025 |
| Watson Robert Eugene | ▲ Buy | Open Market | 2,919 | $20K | 7/25/2025 |
| KERSTEN GEERT R | ▲ Buy | Open Market | 29,197 | $200K | 7/25/2025 |
| TALOR EYAL | ▲ Buy | Grant | 1,048 | $2K | 6/30/2025 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 1,873 | $4K | 6/30/2025 |
| KERSTEN GEERT R | ▲ Buy | Grant | 2,292 | $5K | 6/30/2025 |
| TALOR EYAL | ▲ Buy | Grant | 10,416 | $2K | 3/31/2025 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 15,432 | $4K | 3/31/2025 |
| KERSTEN GEERT R | ▲ Buy | Grant | 22,786 | $5K | 3/31/2025 |
| KERSTEN GEERT R | ▲ Buy | Grant | 12,940 | $5K | 12/31/2024 |
| TALOR EYAL | ▲ Buy | Grant | 6,001 | $2K | 12/31/2024 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 10,727 | $4K | 12/31/2024 |
| TALOR EYAL | ▲ Buy | Grant | 2,264 | $2K | 9/30/2024 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 4,047 | $4K | 9/30/2024 |
| KERSTEN GEERT R | ▲ Buy | Grant | 4,882 | $5K | 9/30/2024 |
| KERSTEN GEERT R | ▲ Buy | Grant | 4,461 | $5K | 6/28/2024 |
| TALOR EYAL | ▲ Buy | Grant | 2,068 | $2K | 6/28/2024 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 3,698 | $4K | 6/28/2024 |
| Watson Robert Eugene | ▲ Buy | Open Market | 20,000 | $28K | 5/8/2024 |
| PRICHEP PATRICIA B | ▲ Buy | Open Market | 8,000 | $11K | 5/8/2024 |
| KERSTEN GEERT R | ▲ Buy | Open Market | 30,000 | $42K | 5/8/2024 |
| TALOR EYAL | ▲ Buy | Grant | 1,256 | $2K | 3/29/2024 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 2,246 | $4K | 3/29/2024 |
| KERSTEN GEERT R | ▲ Buy | Grant | 2,709 | $5K | 3/29/2024 |
| TALOR EYAL | ▲ Buy | Grant | 882 | $2K | 12/29/2023 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 1,577 | $4K | 12/29/2023 |
| KERSTEN GEERT R | ▲ Buy | Grant | 1,819 | $5K | 12/29/2023 |
| TALOR EYAL | ▲ Buy | Grant | 1,920 | $2K | 9/29/2023 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 3,432 | $4K | 9/29/2023 |
| KERSTEN GEERT R | ▲ Buy | Grant | 3,960 | $5K | 9/29/2023 |
| TALOR EYAL | ▲ Buy | Grant | 995 | $2K | 6/30/2023 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 1,780 | $4K | 6/30/2023 |
| KERSTEN GEERT R | ▲ Buy | Grant | 2,053 | $5K | 6/30/2023 |
| KERSTEN GEERT R | ▲ Buy | Grant | 2,133 | $5K | 3/31/2023 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 1,849 | $4K | 3/31/2023 |
| TALOR EYAL | ▲ Buy | Grant | 1,034 | $2K | 3/31/2023 |
| TALOR EYAL | ▲ Buy | Grant | 1,021 | $2K | 12/30/2022 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 1,825 | $4K | 12/30/2022 |
| KERSTEN GEERT R | ▲ Buy | Grant | 1,851 | $4K | 12/30/2022 |
| ZIMMERMAN DANIEL H | ▲ Buy | Grant | 1,266 | $4K | 9/30/2022 |
| TALOR EYAL | ▲ Buy | Grant | 776 | $2K | 9/30/2022 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 1,388 | $4K | 9/30/2022 |
| KERSTEN GEERT R | ▲ Buy | Grant | 1,407 | $4K | 9/30/2022 |
| ZIMMERMAN DANIEL H | ▲ Buy | Grant | 876 | $4K | 6/30/2022 |
| TALOR EYAL | ▲ Buy | Grant | 533 | $2K | 6/30/2022 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 953 | $4K | 6/30/2022 |
| KERSTEN GEERT R | ▲ Buy | Grant | 966 | $4K | 6/30/2022 |
| ZIMMERMAN DANIEL H | ▲ Buy | Grant | 1,006 | $4K | 3/31/2022 |
| TALOR EYAL | ▲ Buy | Grant | 610 | $2K | 3/31/2022 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 1,091 | $4K | 3/31/2022 |
| KERSTEN GEERT R | ▲ Buy | Grant | 1,106 | $4K | 3/31/2022 |
| ZIMMERMAN DANIEL H | ▲ Buy | Grant | 557 | $4K | 12/31/2021 |
| TALOR EYAL | ▲ Buy | Grant | 338 | $2K | 12/31/2021 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 604 | $4K | 12/31/2021 |
| KERSTEN GEERT R | ▲ Buy | Grant | 612 | $4K | 12/31/2021 |
| TALOR EYAL | ▼ Sell | Open Market | 15,000 | $169K | 10/19/2021 |
| ZIMMERMAN DANIEL H | ▲ Buy | Grant | 343 | $4K | 9/30/2021 |
| TALOR EYAL | ▲ Buy | Grant | 218 | $2K | 9/30/2021 |
| PRICHEP PATRICIA B | ▲ Buy | Grant | 372 | $4K | 9/30/2021 |
| KERSTEN GEERT R | ▲ Buy | Grant | 395 | $4K | 9/30/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Cel-Sci stock shows high RSI and revenue divergence
Recent data for Cel-Sci Corporation indicates a high RSI reading of 85.6, suggesting the stock may be overbought. The company is also showing a six-month revenue and price divergence. Analysts maintain an average target price of $12.50, which is significantly higher than the current trading levels within the 52-week range.
Cel-Sci stock shows high RSI and revenue divergence. Recent data for Cel-Sci Corporation indicates a high RSI reading of 85.6, suggesting the stock may be overbought. The company is also showing a six-month revenue and price divergence. Analysts maintain an average target price of $12.50, which is significantly higher than the current trading levels within the 52-week range.